ChromaDex Q1 net sales $17.3M (+18% YoY); net loss $7.7M; adj EBITDA loss narrows

Niagen Bioscience, Inc.

2022-Q1 EPS reported -$0.11 revenue$17,259,000

Net sales $17.3M (+18% YoY); Tru Niagen sales $14.9M (+20% from Q1 2021).
Gross margin 61.0% (down from 62.9%); net loss $7.7M ($0.11 per share) vs $7.4M ($0.12) last year.
Adjusted EBITDA loss (incl legal) $4.5M, a $1.2M improvement from Q1 2021.
Launched Tru Niagen Immune in April 2022; new TV campaign with encouraging early results.
Granted U.S. continuation patent covering NR chloride, malate, and tartrate salts through 2037.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.